Yes — diabetes is the leading cause of chronic kidney disease (CKD) and kidney failure globally, accounting for approximately 40 percent of all new dialysis cases in India. Diabetic kidney disease (diabetic nephropathy) develops silently over years — damaging the kidney’s filtration units through sustained elevated blood glucose and high blood pressure — without producing any symptoms until 50 to 70 percent of kidney function has been lost. By the time a patient notices swelling in the legs, persistent fatigue, or changes in urine output, the kidney damage is already advanced. The only way to catch diabetic kidney disease before it causes this level of damage is through specific urine and blood tests that measure kidney function directly — tests that are available at Sangini Hospital in Satellite, Ahmedabad and that every patient with Type 2 diabetes should receive annually.
At Sangini Hospital, Dr Tapan Shah and Dr Harsh Maniar screen every diabetes patient for kidney disease as part of the standard diabetes care protocol — because the window for preventing kidney failure is wide open early and nearly closed by the time symptoms appear.
Can Diabetes Damage Your Kidneys? What Early Detection Tests Catch and Why They Matter
How Diabetes Damages the Kidneys — the Mechanism
Each kidney contains approximately one million tiny filtration units called glomeruli. Each glomerulus is a tuft of capillaries that filters blood under pressure, retaining proteins and cells while allowing waste products and water to pass into the urine. The integrity of this filtration depends on the capillary endothelium being intact and on the pressure within the glomerulus being appropriately regulated.
Sustained elevated blood glucose damages the glomerular filtration apparatus through two converging mechanisms.
- Direct glycation injury: glucose attaches to glomerular proteins — the same non-enzymatic glycation that produces HbA1c — thickening the glomerular basement membrane and disrupting its selective filtration function. The thickened membrane becomes leaky, allowing albumin — a protein that should be retained — to pass into the urine. This is microalbuminuria: the earliest detectable sign of glomerular injury.
- Haemodynamic injury: elevated glucose activates the renin-angiotensin-aldosterone system (RAAS), causing preferential dilation of the afferent (incoming) glomerular arteriole without equivalent dilation of the efferent (outgoing) arteriole. The result is elevated intraglomerular pressure — hyperfiltration — that accelerates mechanical damage to the glomerular capillaries over time. Hypertension, which coexists in the majority of diabetic patients, adds systemic pressure to this intraglomerular hyperfiltration, compounding the damage.
Over years, the damaged glomeruli are progressively replaced by fibrous tissue — glomerulosclerosis. As more glomeruli are lost, the remaining ones compensate by filtering harder — further accelerating their own destruction. This is the self-perpetuating cycle that, without intervention, eventually results in end-stage renal disease requiring dialysis or transplantation.
The Critical Reason Creatinine Rises Late — and Why Microalbumin Is the Earlier Test
Most patients and many non-specialist physicians rely on serum creatinine to monitor kidney function. This is understandable — creatinine is a standard blood test, widely available, and directly measures a waste product the kidneys are supposed to clear. But creatinine is a late marker of kidney damage.
The kidneys have enormous functional reserve. Creatinine begins to rise noticeably only when approximately 50 percent of kidney filtration capacity has been lost — when the GFR (glomerular filtration rate) has fallen from a normal of 90 to 120 mL/min to below 60 mL/min. By the time creatinine is clearly elevated on a standard blood test, the patient has already lost half their kidney function.
Microalbuminuria — a small amount of albumin in the urine, measured as the albumin-to-creatinine ratio (ACR) on a spot urine sample — becomes detectable much earlier, when glomerular damage is still in its early stages and when intervention can prevent or significantly slow progression to CKD.
The clinical significance of the ACR thresholds:
| ACR Value | Classification |
Clinical Meaning
|
| Below 30 mg/g | Normal |
No detectable glomerular albumin leak
|
| 30–300 mg/g | Microalbuminuria |
Early glomerular injury — intervention window is open
|
| Above 300 mg/g | Macroalbuminuria |
Established nephropathy — progression risk is high
|
A single elevated ACR is not diagnostic — it should be confirmed on two of three measurements over three to six months, because transient elevations occur from exercise, fever, and urinary tract infection. A consistently elevated ACR in a diabetic patient is a clear signal to intensify blood glucose control, start RAAS inhibitor therapy, and manage blood pressure to below 130/80 mmHg.
The Five Stages of CKD — Where Diabetic Kidney Disease Sits
Chronic kidney disease is staged by eGFR — the estimated glomerular filtration rate — calculated from serum creatinine, age, sex, and race:
| CKD Stage | eGFR (mL/min/1.73 m²) | Description |
| Stage 1 | ≥ 90 |
Normal or high — kidney damage with microalbuminuria
|
| Stage 2 | 60–89 |
Mildly reduced — often no symptoms
|
| Stage 3a | 45–59 |
Mildly to moderately reduced
|
| Stage 3b | 30–44 |
Moderately to severely reduced
|
| Stage 4 | 15–29 |
Severely reduced — preparation for renal replacement
|
| Stage 5 | Below 15 |
Kidney failure — dialysis or transplant may be required
|
Diabetic nephropathy can be detected at Stage 1 through microalbumin testing — before the eGFR has declined at all. This is the stage where lifestyle and medication intervention produces the most durable protection. By Stage 3b or 4, the focus shifts from prevention of progression to preparation for renal replacement therapy.
At Sangini Hospital in Satellite, Ahmedabad, the annual kidney screening for every diabetic patient includes both eGFR (from serum creatinine) and ACR (from spot urine) — because each provides information the other does not. eGFR tells you how much function remains. ACR tells you how fast the filtration barrier is breaking down. Together they give a complete picture of where a patient sits on the nephropathy progression curve.
RAAS Inhibitors — The First-Line Treatment for Diabetic Nephropathy
Once microalbuminuria is confirmed in a diabetic patient, RAAS inhibitor therapy is initiated — regardless of whether the patient has hypertension. This is one of the most important and most underused interventions in diabetic kidney disease management in India.
ACE inhibitors (ramipril, enalapril) and ARBs (losartan, telmisartan) block the renin-angiotensin-aldosterone system at different points. Their renal protective effect in diabetes goes beyond blood pressure lowering — they specifically reduce intraglomerular hyperfiltration by dilating the efferent arteriole, normalising the elevated intraglomerular pressure that drives mechanical glomerular damage. This haemodynamic protection is separate from any antihypertensive effect and is why these drugs are indicated for all diabetic patients with confirmed microalbuminuria, even those with normal systemic blood pressure.
The clinical evidence is substantial: ACE inhibitors and ARBs reduce the rate of progression from microalbuminuria to macroalbuminuria by approximately 50 percent and significantly delay progression to end-stage renal disease in patients with established diabetic nephropathy.
The combination of an ACE inhibitor and ARB together is not recommended — it produces additive side effects including hyperkalaemia without additional renal benefit, and has been associated with harm in trial data. One or the other, not both.
SGLT2 Inhibitors — Renal Protection Beyond Glucose Lowering
The CREDENCE trial (2019) was the landmark study that established SGLT2 inhibitor (canagliflozin) as a renal-protective medication in diabetic patients with CKD. In patients with Type 2 diabetes and established CKD at baseline, canagliflozin reduced the composite risk of dialysis, kidney transplant, or sustained eGFR below 15 by 34 percent compared to placebo.
The DAPA-CKD trial subsequently showed that dapagliflozin produced significant renal and cardiovascular protection in patients with CKD regardless of whether they had diabetes — establishing SGLT2 inhibitors as genuine kidney-protective agents rather than merely glucose-lowering drugs with incidental renal benefits.
The mechanism of renal protection from SGLT2 inhibitors involves tubuloglomerular feedback — by reducing glucose reabsorption in the proximal tubule and increasing sodium delivery to the macula densa, SGLT2 inhibitors reduce intraglomerular hyperfiltration through a mechanism complementary to RAAS inhibition. They can be used alongside ACE inhibitors or ARBs for additive renal protection.
For patients at Sangini Hospital with diabetic nephropathy and eGFR above 20 mL/min, Dr Harsh Maniar’s clinical research background ensures that SGLT2 inhibitor prescribing reflects this current evidence — adding renal protection that standard diabetes regimens without SGLT2 inhibitors do not provide.
Dietary Considerations for Diabetic Kidney Disease in an Indian Vegetarian Diet
Protein restriction has traditionally been recommended for patients with advanced diabetic nephropathy — reducing dietary protein reduces the nitrogen load the kidneys must excrete and slows the progression of glomerulosclerosis. The standard recommendation is 0.8 grams of protein per kilogram of body weight per day for patients with CKD Stage 3 and above.
For Indian vegetarian patients in Ahmedabad — where dal, legumes, and paneer are primary protein sources — this creates a specific dietary challenge. Unlike meat-based high-protein diets, plant-based protein sources in dal and legumes come packaged with fibre, complex carbohydrates, and potassium that are independently beneficial for cardiometabolic health. The protein restriction should be applied thoughtfully, reducing total protein intake without eliminating the legume-based meals that provide the bulk of nutritional value in a Gujarati vegetarian diet.
High potassium foods — bananas, oranges, coconut water, potatoes — require specific attention in patients with CKD Stage 3b and above, because impaired potassium excretion in advanced CKD produces hyperkalaemia, which increases cardiac arrhythmia risk. Dr Tapan Shah discusses potassium management alongside dietary protein counselling for patients with Stage 3b CKD and above at Sangini Hospital — because the standard Indian dietary advice about fruit and vegetable consumption requires modification in this specific patient group.
Prevention — What Keeps the Kidneys Safe
The interventions with the strongest evidence for preventing and slowing diabetic nephropathy:
- Blood glucose control — HbA1c maintained below 7 percent reduces the rate of microalbuminuria development by approximately 35 percent compared to conventional control. The benefit is greatest when initiated early in the disease course.
- Blood pressure control below 130/80 mmHg — the single most impactful intervention for slowing progression once CKD is established. Every 10 mmHg reduction in systolic blood pressure reduces GFR decline rate meaningfully.
- RAAS inhibitor therapy — for all patients with confirmed microalbuminuria, regardless of blood pressure.
- SGLT2 inhibitor — for patients with eGFR above 20 mL/min and either established CKD or high cardiovascular risk.
- Avoiding nephrotoxic medications — NSAIDs (ibuprofen, naproxen, diclofenac) are commonly used in Ahmedabad for pain management and significantly reduce renal blood flow. Diabetic patients with any degree of CKD should avoid regular NSAID use. Contrast dye used in CT scans and cardiac catheterisation requires specific precautions — adequate pre-hydration and sometimes temporary cessation of Metformin.
- Annual kidney function screening — eGFR and ACR — allows early intervention before the disease advances beyond the reversible stages.
Frequently Asked Questions
Can diabetic kidney disease be reversed?
Early diabetic nephropathy — Stage 1 and Stage 2 with microalbuminuria — can be partially reversed with intensive blood glucose and blood pressure control combined with RAAS inhibitor therapy. The microalbuminuria reduces and sometimes normalises, and eGFR can stabilise or mildly improve. Established glomerulosclerosis in Stage 3 and beyond cannot be reversed — the goal shifts to slowing progression rather than restoring function. This is why the microalbuminuria stage is the critical intervention window.
What does it feel like when diabetes is damaging the kidneys?
Diabetic kidney disease produces no symptoms until function has declined by 50 to 70 percent. When symptoms do appear, they include fatigue, reduced urine output, ankle and leg swelling from fluid retention, breathlessness from fluid accumulating in the lungs, and nausea. By this stage, the patient is typically at CKD Stage 4 or 5. Waiting for symptoms before investigating kidney function means waiting until the damage is advanced and irreversible. Annual ACR and eGFR testing is the only way to catch damage in the treatable phase.
Is the microalbumin test the same as a standard urine test?
No — a standard urine dipstick tests for protein in the gross sense and does not detect the small amounts of albumin that constitute microalbuminuria. Microalbumin testing requires a dedicated immunoassay test on a spot urine sample, measuring albumin in micrograms rather than milligrams. Many laboratories report the albumin-to-creatinine ratio (ACR) rather than albumin alone, which corrects for urine concentration and is more accurate. Requesting a urine protein dipstick rather than a specific ACR is one of the most common reasons early diabetic nephropathy is missed.
Can I take ibuprofen or diclofenac if I have diabetic kidney disease?
NSAID pain medications, including ibuprofen, naproxen, and diclofenac, reduce renal blood flow by inhibiting prostaglandin synthesis in the kidney. In patients with diabetic kidney disease, this reduction in renal perfusion can precipitate acute kidney injury on top of chronic impairment. NSAIDs should be avoided or used only for very brief periods with medical guidance in patients with CKD Stage 2 and above. Paracetamol is the safer analgesic choice for most pain management in this group.
How often should kidney function be tested in a diabetic patient?
Annually — eGFR from a blood test and ACR from a spot urine — for all patients with Type 2 diabetes from the time of diagnosis. If microalbuminuria is already present or eGFR has declined below 60, more frequent monitoring — every three to six months — allows medication adjustments and dietary changes to be made before each successive decline occurs. At Sangini Hospital in Satellite, Ahmedabad, kidney monitoring is integrated into the standard diabetes review rather than arranged separately.
How does Sangini Hospital in Satellite, Ahmedabad screen and manage diabetic kidney disease?
Sangini Hospital provides on-site eGFR, serum creatinine, ACR, and urine microscopy for annual diabetic kidney disease screening. Dr Tapan Shah and Dr Harsh Maniar review results in the context of the full clinical picture — blood pressure, HbA1c, current medications, and dietary patterns — to adjust treatment at each annual review. RAAS inhibitor and SGLT2 inhibitor therapy is initiated where indicated, and dietary guidance for potassium and protein management in advanced CKD is provided at Sangini Hospital’s diabetes care consultations. Book your annual diabetes kidney screening at Sangini Hospital, Satellite, Ahmedabad.
The Window to Protect the Kidneys Is Open Early and Closes Gradually
A patient with microalbuminuria and an eGFR of 85 has every option available to them — intensive blood glucose control, RAAS inhibitors, SGLT2 inhibitors, blood pressure management — and the probability of preventing progression to dialysis over a 20-year horizon is high. A patient who presents with an eGFR of 18 and macroalbuminuria is being prepared for renal replacement therapy. Both patients had diabetes for the same number of years. What differed was when the kidney tests were run.
At Sangini Hospital in Satellite, Ahmedabad, those tests are part of the annual protocol — not an afterthought.
Book your kidney screening and diabetes review today.
📍 Sangini Hospital — 1st Floor, Santorini Square, Satellite, Ahmedabad – 380015 📞 079-40056171 | 📧 support@sanginihospital.com 👨⚕️ Dr Tapan Shah (MD, Consultant Physician) | Dr Harsh Maniar (Internal Medicine & Clinical Research)
For more information, click below: